Everything You Need To Know About A SAFE: The Good News And The Bad News

People who use SAFEs will tell you they're the standard and nobody has a problem with them. Sign it, wire it, move on.

I've sat across the table from a lot of angel investors, and my experience is different. Plenty of them do have a problem with it. They just won't say so out loud.

Both things are true. A SAFE can be exactly the right instrument for your raise. It can also shrink the pool of people willing to write you a check. You need to know both before you pick it.

What is a SAFE, and how does it work?

A SAFE (Simple Agreement for Future Equity) is a contract where an investor gives you money today in exchange for the right to shares later. It isn't debt. There's no maturity date, no interest and no repayment clock.

It waits for a trigger, usually a priced equity round. When that round happens, the SAFE converts into shares at the valuation cap, the discount, or both, whichever you negotiated.

• Valuation cap: the maximum valuation the SAFE converts at, no matter how high the priced round comes in.
• Discount: a percentage off the price new investors pay in the priced round.
• Post-money: the common version today, which makes ownership easier to read before the round.

The good news: why founders love SAFEs

Founders use SAFEs a lot. In 2025, U.S. startups on Carta raised $10.4 billion across more than 50,000 SAFEs and convertible notes. When founders choose between those two, the SAFE usually wins: Carta counted 90% of those pre-seed deals as SAFEs in Q1 2025, up from 88% in Q2 2024.

The paperwork is simpler. The legal cost per check is lower. There's no deadline forcing an awkward conversation 18 months from now. For a founder collecting a handful of small checks, those are real advantages.

The bad news: the market doesn't love it as much as the data says

Look at what that 90% actually measures. It's SAFEs versus convertible notes. Priced rounds aren't in that comparison at all, so the number says nothing about how many investors would rather have a price.

It also comes from startups that run their cap tables on Carta. Those are mostly venture-track companies raising from funds and from angels who've done this a dozen times. Your investors may be the local surgeon, the business owner down the street, or the executive with money to put to work. If so, you're not raising inside that dataset. You're raising in a room that thinks differently.

I've seen this again and again. You pitch the SAFE and the investor nods. They get it in concept and say they're comfortable. Then they pass, and you never hear the real reason.

The real reason isn't logical. It's gut-level. They want a price. Their question is "what am I buying, and what's it worth?" A SAFE answers "we'll figure that out later." To a lot of newer angels and high-net-worth investors, that feels like getting stepped over. Some of them don't want to admit they don't fully understand the instrument, so they walk instead of asking.

That's perceived value versus real value. On paper, the SAFE might be the better deal for them. It doesn't matter if they don't feel it.

There are also real reasons behind the feeling:

• A SAFE holder isn't a shareholder yet, so there are no voting rights until it converts.
• They only get information rights if they negotiated them.
• If a priced round never comes, the SAFE may never convert at all.
• Even the tax treatment is fuzzier. Tax advisors still disagree on whether the QSBS holding-period clock starts when the SAFE is signed or when it converts.

A priced round takes every one of those questions off the table. For the fine print, read the SAFE details most founders never actually read.

SAFE vs. convertible note vs. priced round

What this means for your raise

Pick a SAFE and your market gets smaller. That's the whole message.

It doesn't mean you won't raise, and it doesn't mean it's the wrong instrument. Sometimes it's the best one, especially when you're moving fast, your checks are small and your investors have done this before. A priced round has its own costs: more legal fees, a valuation you have to defend today, and governance conversations you may not be ready for yet.

Go in with your eyes open. A priced equity round will almost always draw more interested investors than a SAFE. If you choose the SAFE, choose it on purpose. Plan for the fact that some of the people who say yes in the meeting will say no by email.

The convertible note isn't the escape hatch

Founders who hear this sometimes reach for a convertible note instead. A note is debt, with a maturity date, an interest rate and a repayment obligation if you don't price a round in time.

Sophisticated, experienced investors are fine with it. They know the maturity date is leverage for them, not a threat. Newer angels and high-net-worth individuals often hate it. To them it's debt that isn't really debt, equity that isn't really equity, and a deadline nobody explained. It's the same perception problem in different packaging, and I break down what happens at maturity in the convertible note trap.

Running the numbers on both instruments

Take a $500K post-money SAFE at a $5M cap. $500K divided by $5M is 10% of the company just before the priced round's new money comes in, and the round itself dilutes that further.

Now take a $500K note. If it uses a $5M pre-money cap, it converts to $500K divided by $5.5M, about 9%, before accrued interest is added. It also carries an 18-month maturity clock. If you cross that line without a priced round, you're negotiating an extension under pressure. The note holder is in a stronger position than on day one.

The math is close. The pressure, and the investor's comfort, are not.

The objection: "SAFEs are standard. Everyone uses them."

They're standard in one market, and that may not be your market. Before you print documents, ask the three or four investors most likely to lead your round which they'd rather hold: a SAFE, a note or priced equity. Their answer is the only data point that matters for your round.

Then have a startup attorney run the actual conversion math at your target valuation before you sign. Ask them three things: what each investor owns after the next round, how the cap and discount interact, and what happens if no priced round ever comes. The lawyer drafts the paperwork. Deciding which instrument your investors will actually say yes to is your job. If you do go priced, know the five term sheet terms that actually matter before you negotiate.

What to do this week

List your four most likely lead investors. Ask each one a single question: SAFE, note or priced equity? Pick your instrument after you hear the answers, not before.

A SAFE is a weapon, and a good one. Just know that when you pick it up, fewer people show up to the fight.

Key takeaways

• A SAFE converts to shares at a future priced round and carries no interest or maturity date.
• Carta's 90% figure compares SAFEs with notes only; priced rounds aren't in it.
• Ask your likely lead investors which instrument they prefer before you print documents.

Frequently asked questions

Is a SAFE debt or equity?

Neither, yet. A SAFE is a contract for future equity. It carries no interest, no maturity date and no repayment obligation, and it converts into shares when a triggering event, usually a priced round, happens.

Do angel investors prefer SAFEs or priced rounds?

Experienced angels are often comfortable with SAFEs. Many newer angels and high-net-worth investors quietly prefer a priced round because they want to know what they're buying and what it's worth, and some pass on a SAFE without saying why.

How much of my company does a $500K SAFE at a $5M cap take?

On a post-money SAFE, $500K divided by a $5M cap is 10% just before the priced round's new money, and the round then dilutes that further. Have a startup attorney model your actual numbers.